Journal
ONCOTARGET
Volume 8, Issue 9, Pages 15553-15562Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.14948
Keywords
extracellular vesicles; proteomics; endothelial dysfunction; hypertension; albuminuria
Categories
Funding
- Instituto de Salud Carlos III [PI070537, IF08/3667-1, PI1102239, PI 14/0917, PI11/01401, PI11/02432, PI13/01873, PI13/01746, PI13/01581, PI14/01650, PI14/01841, PT13/0001/0013, PIE13/00051, PIE13/00045, CP09/00229]
- IDCSalud [3371/002]
- Fundacion Mutua Madrilena
- Fundacion Conchita Rabago de Jimenez Diaz and FONDOS FEDER [RD06/0014/1015, RD12/0042/0071]
Ask authors/readers for more resources
Despite of the great advances in anti-hypertensive therapies, many patients under Renin-Angiotensin-System (RAS) suppression develop albuminuria, which is a clear indicator of therapeutic inefficiency. Hence, indicators of vascular function are needed to assess patients' condition and help deciding future therapies. Proteomic analysis of circulating extracellular vesicles (EVs) showed two proteins, kalirin and chromodomain-helicase-DNA-binding protein 7 (CHD7), increased in albuminuric patients. A positive correlation of both with the expression of the endothelial activation marker E-selectin was found in EVs. In vitro analysis using TNFa-treated adult human endothelial cells proved their involvement in endothelial cell activation. Hence, we propose protein levels of kalirin and CHD7 in circulating EVs as novel endothelial dysfunction markers to monitor vascular condition in hypertensive patients with albuminuria.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available